UBS Maintains Neutral on Quest Diagnostics, Raises Price Target to $220

Benzinga Newsdesk www.benzinga.com Positive 69.5%

Neg 0% Neu 0% Pos 69.5%

UBS analyst Kevin Caliendo maintains Quest Diagnostics (NYSE:DGX) with a Neutral and raises the price target from $210 to $220.